A Phase 3 interventional study of Sotagliflozin and Insulin glargine (HOE901) in Type 2 Diabetes Mellitus, sponsored by Lexicon Pharmaceuticals. Completed at 106 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by Lexicon Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. sotagliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 9 that started in 2017, is one of 13 in phase 3, and was the 14th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Baylor Research Institute · Sites in United States
Ages 18–84
Allied Hospital Faisalabad · Sites in Pakistan
Ages 30–65
AdventHealth Translational Research Institute · Sites in United States
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
sotagliflozin: first FDA approval 2023 (INPEFA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 571 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 208 across the 28 interventional studies. Of the 25 that completed or were terminated, 13 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 28 have an industry lead sponsor. The 5 most frequent:
Lexicon Pharmaceuticals is the lead sponsor of 61 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
17 studies in Diabetes Mellitus, Type 2 by Lexicon Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 17 studies in Diabetes Mellitus, Type 2 by Lexicon Pharmaceuticals, this one is the 6th largest by enrollment, is one of 7 that started in 2017, is one of 11 in phase 3, and was the 12th registered.
Lexicon Pharmaceuticals’s Diabetes Mellitus, Type 2 studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Lexicon Pharmaceuticals’s 17 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1C (HbA1c) reduction in participants with type 2 diabetes mellitus (T2D) who have inadequate glycemic control on basal insulin alone or with oral antidiabetes drugs (OADs).
Secondary Objectives:
Up to 60 weeks (Screening phase of up to 2 weeks, a 4-week Lantus titration/single-blind placebo Run-in phase), a 52-week double blind Treatment Period, and a 2-week post-treatment Follow-up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a 4-week run-in period, participants were randomized to matching placebo to sotagliflozin 200 milligrams (mg) administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
Drug: Insulin glargine (HOE901) · Drug: Placebo · Drug: Oral Antidiabetes Drugs (OADs)
Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
Drug: Sotagliflozin · Drug: Insulin glargine (HOE901) · Drug: Placebo · Drug: Oral Antidiabetes Drugs (OADs)
Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
Drug: Sotagliflozin · Drug: Insulin glargine (HOE901) · Drug: Oral Antidiabetes Drugs (OADs)
Pharmaceutical form: Tablet Route of administration: Oral
Also known as: SAR439954
Pharmaceutical form: Solution Route of administration: Subcutaneous
Also known as: Lantus
Pharmaceutical form: Tablet Route of administration: Oral
OADs (including metformin) as prescribed by the investigator as per local labeling.
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18
An analysis of covariance (ANCOVA) model was used for the analysis.
Time frame: Baseline and Week 18
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18
FPG was performed in fasting state, that is, without any food intake (except for water) for at least 8 hours. An ANCOVA model was used for the analysis.
Time frame: Baseline and Week 18
Change From Baseline in Body Weight at Week 18
An ANCOVA model was used for the analysis.
Time frame: Baseline and Week 18
Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg at Week 12
An ANCOVA model was used for the analysis. Here, N is the number of participants with data available at a given time point.
Time frame: Baseline and Week 12
Change From Baseline in SBP at Week 12 for All Participants
An ANCOVA model was used for the analysis.
Time frame: Baseline to Week 12
Change From Baseline in HbA1c at Week 52
An ANCOVA model was used for the analysis.
Time frame: Baseline and Week 52
Change From Baseline in Body Weight at Week 52
An ANCOVA model was used for the analysis.
Time frame: Baseline and Week 52
Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participants or clinical investigation participants administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: First dose of study drug to last dose of study drug (up to 55.7 weeks) + 2 weeks
Percentage of Participants With Hypoglycemic Events
Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\]; Severe \[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\] or documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\].
Time frame: Up to 55.7 weeks
Participants took part in the study at 101 investigative sites in the United States, Bulgaria, Canada, Czech Republic, France, Hungary, Slovakia, the United Kingdom from 15 September 2017 to 27 September 2019.
| Milestone | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Started | 144 | 141 | 286 |
| Treated | 144 | 141 | 285 |
| Completed | 129 | 130 | 249 |
| Not completed | 15 | 11 | 37 |
| Withdrew: At the participant's own request | 10 | 5 | 21 |
| Withdrew: Adverse event | 2 | 2 | 6 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Reason not specified | 3 | 4 | 8 |
An analysis of covariance (ANCOVA) model was used for the analysis.
| percentage of HbA1c | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 | -0.27 ± 0.073 | -0.72 ± 0.073 | -0.81 ± 0.056 |
FPG was performed in fasting state, that is, without any food intake (except for water) for at least 8 hours. An ANCOVA model was used for the analysis.
| milligram per deciliter (mg/dL) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 | 12.882 ± 3.6045 | -2.975 ± 3.6083 | -8.949 ± 2.7550 |
An ANCOVA model was used for the analysis.
| kilogram (kg) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 18 | 0.36 ± 0.249 | -0.73 ± 0.250 | -1.37 ± 0.190 |
An ANCOVA model was used for the analysis. Here, N is the number of participants with data available at a given time point.
| mmHg | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg at Week 12 | -4.67 ± 1.470 | -8.58 ± 1.447 | -8.50 ± 1.103 |
An ANCOVA model was used for the analysis.
| mmHg | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Change From Baseline in SBP at Week 12 for All Participants | -0.21 ± 1.120 | -5.15 ± 1.117 | -4.10 ± 0.867 |
An ANCOVA model was used for the analysis.
| percentage of HbA1c | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Change From Baseline in HbA1c at Week 52 | 0.00 ± 0.279 | -0.52 ± 0.152 | -0.57 ± 0.114 |
An ANCOVA model was used for the analysis.
| kg | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 52 | -0.18 ± 0.579 | -1.19 ± 0.620 | -0.83 ± 0.374 |
An AE is any untoward medical occurrence in a participants or clinical investigation participants administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| percentage of participants | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 64.6 | 54.6 | 59.3 |
Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\]; Severe \[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\] or documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\].
| percentage of participants | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Any hypoglycemia | 62.5 | 56.0 | 62.8 |
| Documented symptomatic hypoglycemia | 44.4 | 41.8 | 46 |
| Severe or documented symptomatic hypoglycemia | 44.4 | 41.8 | 46 |
Collected over Deaths: Up to approximately 60 weeks; Adverse Events: First dose of study drug to last dose of study drug (up to 55.7 weeks) + 2 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/144 (1.4%) | 16/144 (11.1%) | 30/144 (20.8%) |
| Sotagliflozin 200 mg | 1/141 (0.7%) | 19/141 (13.5%) | 18/141 (12.8%) |
| Sotagliflozin 400 mg | 6/285 (2.1%) | 28/285 (9.8%) | 45/285 (15.8%) |
| Event | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 3/144 | 0/141 | 0/285 |
| Back painMusculoskeletal and connective tissue disorders | 0/144 | 2/141 | 0/285 |
| Acute myocardial infarctionCardiac disorders | 2/144 | 0/141 | 2/285 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/144 | 1/141 | 0/285 |
| Adenocarcinoma pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/144 | 1/141 | 0/285 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/144 | 1/141 | 0/285 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/144 | 1/141 | 0/285 |
| Postoperative thrombosisInjury, poisoning and procedural complications | 0/144 | 1/141 | 0/285 |
| Angina unstableCardiac disorders | 1/144 | 1/141 | 0/285 |
| Atrial flutterCardiac disorders | 0/144 | 1/141 | 0/285 |
| Event | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/144 | 9/141 | 14/285 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 9/144 | 4/141 | 10/285 |
| Upper respiratory tract infectionInfections and infestations | 8/144 | 1/141 | 14/285 |
| Urinary tract infectionInfections and infestations | 8/144 | 6/141 | 11/285 |
Intent-to-treat (ITT) population included all randomized participants irrespective of compliance with the study protocol and procedures.
| Age, Continuous(years) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 8.9 | 62.1 ± 10.2 | 62.7 ± 9.1 | 62.4 ± 9.4 |
| Sex: Female, Male(Participants) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg | Total |
|---|---|---|---|---|
| Female | 58 | 65 | 132 | 255 |
| Male | 86 | 76 | 154 | 316 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 12 | 25 | 42 | 79 |
| Not Hispanic or Latino | 129 | 113 | 239 | 481 |
| Unknown or Not Reported | 3 | 3 | 5 | 11 |
| Race (NIH/OMB)(Participants) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 2 | 5 |
| Asian | 9 | 1 | 6 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 3 | 3 |
| Black or African American | 10 | 10 | 27 | 47 |
| White | 117 | 124 | 234 | 475 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 5 | 5 | 13 | 23 |
| Region of Enrollment(participants) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg | Total |
|---|---|---|---|---|
| Bulgaria | 9 | 13 | 35 | 57 |
| Canada | 7 | 6 | 16 | 29 |
| Czechia | 14 | 11 | 24 | 49 |
| France | 8 | 8 | 14 | 30 |
| Hungary | 12 | 13 | 21 | 46 |
| Slovakia | 24 | 21 | 32 | 77 |
| United Kingdom | 0 | 0 | 4 | 4 |
| United States | 70 | 69 | 140 | 279 |
| Hemoglobin A1c (HbA1c)(percentage of HbA1c) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg | Total |
|---|---|---|---|---|
| Mean | 8.76 ± 0.79 | 8.76 ± 0.83 | 8.69 ± 0.80 | 8.72 ± 0.80 |
| Systolic Blood Pressure (SBP)(millimeter of Mercury (mmHg)) | Placebo | Sotagliflozin 200 mg | Sotagliflozin 400 mg | Total |
|---|---|---|---|---|
| Mean | 137.59 ± 14.12 | 136.40 ± 15.54 | 135.84 ± 14.95 | 136.42 ± 14.89 |
Showing the first 100 of 106 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Sep 2019, 24 months.
Results were first posted in May 2021, 1 year 7 months after primary completion. A results delay was requested in Aug 2020.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotagliflozin